全文获取类型
收费全文 | 970篇 |
免费 | 41篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 21篇 |
妇产科学 | 18篇 |
基础医学 | 157篇 |
口腔科学 | 76篇 |
临床医学 | 78篇 |
内科学 | 255篇 |
皮肤病学 | 10篇 |
神经病学 | 99篇 |
特种医学 | 72篇 |
外科学 | 88篇 |
综合类 | 14篇 |
预防医学 | 37篇 |
眼科学 | 3篇 |
药学 | 62篇 |
中国医学 | 3篇 |
肿瘤学 | 27篇 |
出版年
2022年 | 9篇 |
2021年 | 11篇 |
2020年 | 21篇 |
2019年 | 18篇 |
2018年 | 17篇 |
2017年 | 15篇 |
2016年 | 13篇 |
2015年 | 24篇 |
2014年 | 37篇 |
2013年 | 35篇 |
2012年 | 50篇 |
2011年 | 47篇 |
2010年 | 24篇 |
2009年 | 25篇 |
2008年 | 39篇 |
2007年 | 50篇 |
2006年 | 39篇 |
2005年 | 18篇 |
2004年 | 28篇 |
2003年 | 33篇 |
2002年 | 22篇 |
2001年 | 14篇 |
2000年 | 23篇 |
1999年 | 17篇 |
1998年 | 28篇 |
1997年 | 23篇 |
1996年 | 20篇 |
1995年 | 19篇 |
1994年 | 9篇 |
1993年 | 14篇 |
1992年 | 19篇 |
1991年 | 13篇 |
1990年 | 18篇 |
1989年 | 19篇 |
1988年 | 24篇 |
1987年 | 19篇 |
1986年 | 21篇 |
1985年 | 24篇 |
1984年 | 15篇 |
1983年 | 13篇 |
1982年 | 12篇 |
1981年 | 6篇 |
1980年 | 10篇 |
1979年 | 16篇 |
1978年 | 4篇 |
1977年 | 10篇 |
1976年 | 7篇 |
1975年 | 7篇 |
1974年 | 8篇 |
1973年 | 5篇 |
排序方式: 共有1025条查询结果,搜索用时 25 毫秒
41.
M Storr P Born E Frimberger N Weigert T Rösch A Meining M Classen HD Allescher 《BMC gastroenterology》2002,2(1):19-8
Background
It has been suggested that intrasphincteric injection of botulinum toxin (BTX) may represent an alternative therapy to balloon dilatation in achalasia. The aim of the present study was to test the effectiveness of botulinum toxin injections in achalasia patients, as assessed using lower oesophageal sphincter pressure (LOSP) and symptom scores, and to compare the response in patients with different types of pretreatment (no previous treatment, balloon dilatation, myotomy, BTX injection). 相似文献42.
Monika Engelhardt Evangelos Terpos Martina Kleber Francesca Gay Ralph W?sch Gareth Morgan Michele Cavo Niels van de Donk Andreas Beilhack Benedetto Bruno Hans Erik Johnsen Roman Hajek Christoph Driessen Heinz Ludwig Meral Beksac Mario Boccadoro Christian Straka Sara Brighen Martin Gramatzki Alessandra Larocca Henk Lokhorst Valeria Magarotto Fortunato Morabito Meletios A. Dimopoulos Hermann Einsele Pieter Sonneveld Antonio Palumbo 《Haematologica》2014,99(2):232-242
Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE system for level of evidence. All patients with symptomatic disease should undergo risk stratification to classify patients for International Staging System stage (level of evidence: 1A) and for cytogenetically defined high- versus standard-risk groups (2B). Novel-agent-based induction and up-front autologous stem cell transplantation in medically fit patients remains the standard of care (1A). Induction therapy should include a triple combination of bortezomib, with either adriamycin or thalidomide and dexamethasone (1A), or with cyclophosphamide and dexamethasone (2B). Currently, allogeneic stem cell transplantation may be considered for young patients with high-risk disease and preferably in the context of a clinical trial (2B). Thalidomide (1B) or lenalidomide (1A) maintenance increases progression-free survival and possibly overall survival (2B). Bortezomib-based regimens are a valuable consolidation option, especially for patients who failed excellent response after autologous stem cell transplantation (2A). Bortezomib-melphalan-prednisone or melphalan-prednisone-thalidomide are the standards of care for transplant-ineligible patients (1A). Melphalan-prednisone-lenalidomide with lenalidomide maintenance increases progression-free survival, but overall survival data are needed. New data from the phase III study (MM-020/IFM 07-01) of lenalidomide-low-dose dexamethasone reached its primary end point of a statistically significant improvement in progression-free survival as compared to melphalan-prednisone-thalidomide and provides further evidence for the efficacy of lenalidomide-low-dose dexamethasone in transplant-ineligible patients (2B). 相似文献
43.
Hans D de Boer Jan van Egmond Jacques J Driessen Leo HD Booij 《Neuropsychiatric Disease and Treatment》2007,3(5):539-544
Steroidal neuromuscular blocking agents (NMBAs), such as rocuronium, are widely used in clinical anesthesia and emergency medicine to facilitate endotracheal intubation and artificial ventilation and to allow surgical access to body cavities. Reversal of neuromuscular blockade is important for the acceleration of patient recovery and prevention of postoperative residual neuromuscular blockade and reduces the incidence of severe morbidity and mortality associated with anesthesia management. Sugammadex is the first selective relaxant binding agent (SRBA) and has been designed to reverse the steroidal neuromuscular blocking drug rocuronium. Encapsulation of the rocuronium molecule by sugammadex results in a rapid decrease in free rocuronium in the plasma and subsequently at the nicotinic receptor at the motor endplate. After encapsulation, rocuronium is not available to bind to the nicotinic receptor in the neuromuscular junction. This promotes the liberation of acetylcholine receptors, and muscle activity reappears. This new concept of reversal of neuromuscular block induced by rocuronium (or vecuronium) led to impressive results in animal and phase 1 and 2 studies. Sugammadex is currently in phase 3 clinical studies and may be commercially available by 2008. 相似文献
44.
Mohlman J de Jesus M Gorenstein EE Kleber M Gorman JM Papp LA 《Journal of anxiety disorders》2004,18(3):275-290
Eighty treatment-seeking adults age 60 or over with panic disorder, generalized anxiety disorder, and mixed anxiety states (generalized anxiety with panic attacks, panic disorder with secondary generalized anxiety) completed a clinical assessment and battery of self report measures. Several hypotheses were tested from the domains of distinguishing symptoms, associated features, and rates of comorbidity with other disorders. Greater between- than within-group variance was found on a subset of measures suggesting that the distinction between GAD and PD is generally valid in the older adult population. Higher scores on measures of sympathetic arousal, agoraphobic avoidance, and rates of comorbid somatization disorder and alcohol dependence distinguished those with PD from those with GAD. Higher scores on measures of depression and hostility, but not trait anxiety or worry, distinguished the GAD group. Results indicate that distinguishing features of GAD and PD in older treatment-seeking adults may be fewer and slightly different from those of younger adults. 相似文献
45.
Large‐scale brain network abnormalities in Huntington's disease revealed by structural covariance 下载免费PDF全文
Lora Minkova Simon B. Eickhoff Ahmed Abdulkadir Christoph P. Kaller Jessica Peter Elisa Scheller Jacob Lahr Raymund A. Roos Alexandra Durr Blair R. Leavitt Sarah J. Tabrizi Stefan Klöppel TRACK‐HD Investigators 《Human brain mapping》2016,37(1):67-80
Huntington's disease (HD) is a progressive neurodegenerative disorder that can be diagnosed with certainty decades before symptom onset. Studies using structural MRI have identified grey matter (GM) loss predominantly in the striatum, but also involving various cortical areas. So far, voxel‐based morphometric studies have examined each brain region in isolation and are thus unable to assess the changes in the interrelation of brain regions. Here, we examined the structural covariance in GM volumes in pre‐specified motor, working memory, cognitive flexibility, and social‐affective networks in 99 patients with manifest HD (mHD), 106 presymptomatic gene mutation carriers (pre‐HD), and 108 healthy controls (HC). After correction for global differences in brain volume, we found that increased GM volume in one region was associated with increased GM volume in another. When statistically comparing the groups, no differences between HC and pre‐HD were observed, but increased positive correlations were evident for mHD, relative to pre‐HD and HC. These findings could be explained by a HD‐related neuronal loss heterogeneously affecting the examined network at the pre‐HD stage, which starts to dominate structural covariance globally at the manifest stage. Follow‐up analyses identified structural connections between frontoparietal motor regions to be linearly modified by disease burden score (DBS). Moderator effects of disease load burden became significant at a DBS level typically associated with the onset of unequivocal HD motor signs. Together with existing findings from functional connectivity analyses, our data indicates a critical role of these frontoparietal regions for the onset of HD motor signs. Hum Brain Mapp 37:67–80, 2016. © 2015 Wiley Periodicals, Inc. 相似文献
46.
47.
Relationship of polymorphisms in the renin-angiotensin system and in E-selectin of patients with early severe coronary heart disease 总被引:8,自引:0,他引:8
K. Wenzel A. Blackburn M. Ernst M. Affeldt R. Hanke G. Baumann S. B. Felix F. X. Kleber K. Rohde C. Gläser A. Speer 《Journal of molecular medicine (Berlin, Germany)》1997,75(1):57-61
Previous association studies between angiotensin-converting enzyme (ACE) and angiotensinogen (AGT) polymorphisms and several
cardiovascular diseases have reported variable results. Therefore we examined the association of the DNA variants of ACE and
AGT with early, severe coronary heart disease (CHD). In addition, we compared the genotypes of both polymorphisms and the
recently discovered polymorphism in the E-selectin gene in both patients and an unselected population. This study included
113 patients with severe CHD (50 years old or less) and up to 197 control subjects. The frequencies of the ACE I/D variants
were 48% I and 52% D in the controls and 46% I and 54% D in the patients. The frequencies of the AGT-M235T polymorphism were
60.8% M and 39.2% T in controls and 49.1% M and 50.9% T in the patients. The frequencies of the S128R polymorphism of the
E-selectin were 91.3% S and 8.7% R in controls and 84.5% S and 15.5% R in the patients. In our studies the DD genotype of
ACE was not associated with early severe CHD. We found a correlation between the M235T molecular variant of AGT and the S128R
variant of E-selectin to early severe CHD.
Received: 15 February 1996 / Accepted: 2 October 1996 相似文献
48.
The biotransformation of crotonobetaine and D(+)-carnitine into L(-)-carnitine is affected by salt stress in the resting cells of E. coli O44 K74 and the transformed E. coli K38 pT7-5KE32. A yield of 65 and 80% of L(-)-carnitine, respectively, were obtained with 0.5 M NaCl with the wild and transformed strain compared with the 40% obtained with the control. Higher salt levels reduced the conversion. In L(-)-carnitine transport studies using both strains, the transformed strain presented slightly lower apparent K(m) and V values. Arsenate reduced both the transport and biotransformation of crotono-betaine in the presence or absence of 0.5 M NaCl, whereas vanadate only inhibited these processes under salt stress conditions. Hg(II) inhibited both the transport and biotransformation and Pb(II) reduced the biotransformation only under salt stress conditions. Cu(II) produced a significantly higher decrease than Pb(II) in the biotransformation with both substrates in the absence of salt stress conditions, but only affected transport in the presence of such conditions. Furthermore, salt stress affected the CaiT transporter for L(-)-carnitine and crotonobetaine and induced ProU and ProP in the absence of the inducer of the L(-)-carnitine metabolism. It is highly likely that the increase in L(-)-carnitine production was not only due to improved transport but also to the permeabilization effect caused by NaCl, as transport and 1-N-phenylnaphthylamine uptake studies revealed. 相似文献
49.
50.
Sandra D. Comer Maria A. Sullivan Suzanne K. Vosburg Jeanne Manubay Leslie Amass Ziva D. Cooper Phillip Saccone Herbert D. Kleber 《Addiction (Abingdon, England)》2010,105(4):709-718
Background Sublingual buprenorphine is an effective maintenance treatment for opioid dependence, yet intravenous buprenorphine misuse occurs. A buprenorphine/naloxone formulation was developed to mitigate this misuse risk. This randomized, double‐blind, cross‐over study was conducted to assess the intravenous abuse potential of buprenorphine/naloxone compared with buprenorphine in buprenorphine‐maintained injection drug users (IDUs). Methods Intravenous heroin users (n = 12) lived in the hospital for 8–9 weeks and were maintained on each of three different sublingual buprenorphine doses (2 mg, 8 mg, 24 mg). Under each maintenance dose, participants completed laboratory sessions during which the reinforcing and subjective effects of intravenous placebo, naloxone, heroin and low and high doses of buprenorphine and buprenorphine/naloxone were examined. Every participant received each test dose under the three buprenorphine maintenance dose conditions. Results Intravenous buprenorphine/naloxone was self‐administered less frequently than buprenorphine or heroin (P < 0.0005). Participants were most likely to self‐administer drug intravenously when maintained on the lowest sublingual buprenorphine dose. Subjective ratings of ‘drug liking’ and ‘desire to take the drug again’ were lower for buprenorphine/naloxone than for buprenorphine or heroin (P = 0.0001). Participants reported that they would pay significantly less money for buprenorphine/naloxone than for buprenorphine or heroin (P < 0.05). Seven adverse events were reported; most were mild and transient. Conclusions These data suggest that although the buprenorphine/naloxone combination has intravenous abuse potential, that potential is lower than it is for buprenorphine alone, particularly when participants received higher maintenance doses and lower buprenorphine/naloxone challenge doses. Buprenorphine/naloxone may be a reasonable option for managing the risk for buprenorphine misuse during opioid dependence treatment. 相似文献